IBDEI141 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18538,1,3,0)
 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
 ;;^UTILITY(U,$J,358.3,18538,1,4,0)
 ;;=4^E74.39
 ;;^UTILITY(U,$J,358.3,18538,2)
 ;;=^5002928
 ;;^UTILITY(U,$J,358.3,18539,0)
 ;;=E83.30^^94^908^46
 ;;^UTILITY(U,$J,358.3,18539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18539,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,18539,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,18539,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,18540,0)
 ;;=E83.51^^94^908^28
 ;;^UTILITY(U,$J,358.3,18540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18540,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,18540,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,18540,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,18541,0)
 ;;=E83.52^^94^908^26
 ;;^UTILITY(U,$J,358.3,18541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18541,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,18541,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,18541,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,18542,0)
 ;;=E87.5^^94^908^27
 ;;^UTILITY(U,$J,358.3,18542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18542,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,18542,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,18542,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,18543,0)
 ;;=E89.2^^94^908^48
 ;;^UTILITY(U,$J,358.3,18543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18543,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,18543,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,18543,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,18544,0)
 ;;=E89.6^^94^908^47
 ;;^UTILITY(U,$J,358.3,18544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18544,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,18544,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,18544,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,18545,0)
 ;;=L68.0^^94^908^25
 ;;^UTILITY(U,$J,358.3,18545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18545,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,18545,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,18545,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,18546,0)
 ;;=M80.00XA^^94^908^2
 ;;^UTILITY(U,$J,358.3,18546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18546,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,18546,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,18546,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,18547,0)
 ;;=M81.0^^94^908^3
 ;;^UTILITY(U,$J,358.3,18547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18547,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,18547,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,18547,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,18548,0)
 ;;=M85.80^^94^908^44
 ;;^UTILITY(U,$J,358.3,18548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18548,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,18548,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,18548,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,18549,0)
 ;;=N62.^^94^908^24
 ;;^UTILITY(U,$J,358.3,18549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18549,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,18549,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,18549,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,18550,0)
 ;;=E10.43^^94^908^6
 ;;^UTILITY(U,$J,358.3,18550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18550,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,18550,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,18550,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,18551,0)
 ;;=E10.59^^94^908^4
 ;;^UTILITY(U,$J,358.3,18551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18551,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
